Complementary Medicine Journal (CMJA)

Volume 16, Issue 1

Original Article

The Effect of Electroconvulsive Therapy on the Cognitive Status of Schizophrenic Patients

Aqdas al-Sadat Alavian1, Yasmin Ghelichi2, Mohammad Zaman Kamkar3*

  1. Psychiatry Resident, Golestan Research Center of Psychiatry, Faculty of Medicine, Golestan University of Medical Sciences, Gorgan, Iran² Anesthesiologist, North Khorasan University of Medical Sciences, Bojnord, Iran³ Associate Professor of Psychiatry, Department of Psychiatry, Golestan Research Center of Psychiatry, Golestan University of Medical Sciences, Gorgan, Iran

* Corresponding author: Mohammad Zaman Kamkar; Email: M-kamkar72@yahoo.com

DOI: 10.22034/cmja.16.1.73 | Complementary Medicine Journal. 2026;16(1):73–82

Received: 20 May 2026 | Accepted: 16 July 2026

Abstract

Introduction: Despite the beneficial effects of electroconvulsive therapy (ECT) in patients with schizophrenia, uncertainty remains regarding its impact on cognitive impairment. This study investigated the effects of ECT on the cognitive status of hospitalized patients with schizophrenia in Gorgan, Iran.

Methods: This quasi-experimental study used a pretest–posttest design. Twenty-five hospitalized patients diagnosed with schizophrenia according to DSM-5 criteria and meeting the clinical indications for ECT were recruited by convenience sampling. The Montreal Cognitive Assessment (MoCA) and Mini-Mental State Examination (MMSE) were administered 1 hour before the first ECT session and 3 hours after a six-session course. Data were analyzed using SPSS version 16, with chi-square, paired t-test, analysis of variance, and Pearson correlation tests.

Results: Participants had a mean age of 36.72 ± 10.08 years, and 56% were female. Mean MoCA scores increased from 18.00 ± 2.75 to 21.00 ± 3.13, while mean MMSE scores increased from 19.88 ± 2.69 to 21.92 ± 2.78 (p=0.001). No significant associations were found between demographic or ECT-related variables and cognitive scores (p>0.05).

Conclusion: A course of ECT may improve cognitive deficits in patients with schizophrenia. The findings did not indicate a negative effect on memory function.

Keywords: Electroconvulsive therapy; Schizophrenia; Cognitive disorders

Introduction

Schizophrenia is a severe and disabling brain disorder characterized by psychotic symptoms, variable cognitive impairment, and substantial psychosocial consequences. Patients commonly perform 1–2 standard deviations below healthy individuals on neurocognitive tests, particularly in memory, attention, working memory, problem-solving, information-processing speed, and social cognition. These deficits are associated with social isolation, communication difficulties, reduced success in psychosocial rehabilitation, and impaired occupational functioning. Second-generation antipsychotics have not consistently produced substantial improvements in these cognitive deficits. [1- 3]

Electroconvulsive therapy (ECT) is an effective treatment for treatment-resistant psychiatric disorders, including mood disorders and schizophrenia. However, concerns about its cognitive adverse effects, especially memory impairment, remain an important limitation. Since ECT was introduced in 1938, technical modifications have aimed to improve efficacy and reduce cognitive adverse effects, but cognitive impairment continues to be reported. Although some effects are transient and resolve after treatment, concerns remain about possible longer-term consequences. Electrode placement, waveform, electrical dose, and treatment frequency have been identified as factors that may influence cognitive outcomes. [4 -18]

Bilateral ECT has generally been associated with greater cognitive impairment than unilateral ECT, although findings regarding executive function are not uniform. Given the continuing uncertainty about the cognitive effects of ECT, this study evaluated cognitive status in patients with schizophrenia hospitalized at 5th Azar Hospital in Gorgan, Iran, in 2020. [19-22]

Methods

This quasi-experimental study used a pretest–posttest design. It included 25 patients with schizophrenia diagnosed according to DSM-5 criteria who were hospitalized in the psychiatric ward of 5th Azar Hospital, Gorgan, Iran, between October and December 2020 and had a clinical indication for ECT. The sample size was estimated with reference to Seow et al. (2019), using cognitive-score means and standard deviations, a 95% confidence level, and correlation assumptions of r=0.40 and r=0.75. The estimated sample-size range was 19–25; therefore, 25 patients were enrolled. [23]

Inclusion criteria were age 18–50 years, a psychiatrist-confirmed DSM-5 diagnosis of schizophrenia, at least middle-school education, and written informed consent from a parent or legal guardian. Exclusion criteria included major cognitive impairment before ECT (e.g., dementia or delirium), brain surgery, stroke, seizures, changes in medication type or dose during the six ECT sessions, failure to complete follow-up, discharge against medical advice, or withdrawal from the study.

After eligibility screening and explanation of the study, written informed consent was obtained from patients’ parents or legal guardians. Demographic and clinical information was recorded. Cognitive function was assessed using the Montreal Cognitive Assessment (MoCA) and Mini-Mental State Examination (MMSE), administered 1 hour before the first ECT session. Each patient received six ECT sessions on alternate days. The MoCA and MMSE were repeated 3 hours after the final session, once full alertness had been confirmed.

The MoCA, developed by Nasreddine and colleagues in 1996, assesses memory, attention, visuospatial ability, executive function, language, and orientation. Its total score ranges from 0 to 30; scores below 26 indicate cognitive impairment. The Persian version has demonstrated acceptable reliability. The MMSE assesses orientation, registration, attention and concentration, recall, naming, language, reading, writing, and visuoconstruction. Its score also ranges from 0 to 30; scores of 24 or higher are generally considered normal, 20–23 indicate mild impairment, 10–19 moderate impairment, and 0–9 severe impairment. [24- 28]

The demographic checklist included age, sex, medication history, education, marital status, illness duration, and previous ECT. Electrical energy delivered during ECT (joules) and seizure duration were recorded for each patient. The study was approved by the Ethics Committee of Golestan University of Medical Sciences (IR.GOUMS.REC.1399.287). Participants and their legal guardians were assured that information would remain confidential and that they could withdraw at any stage.

Data were analyzed using SPSS version 16. Quantitative and qualitative variables were described using means, standard deviations, frequencies, and percentages. Normality was assessed using the Shapiro–Wilk test. Paired t-tests and analysis of variance were used to compare total and domain-specific MoCA and MMSE scores before and after treatment. Categorical variables were analyzed using the chi-square test. Pearson correlation was used to examine associations of age, illness duration, delivered electrical energy, and seizure duration with MoCA and MMSE scores. A p-value below 0.05 was considered statistically significant.

Results

The mean age was 36.72 ± 10.08 years. Most participants were female (56%) and had less than a high-school diploma (52%). Mean illness duration was 13.56 ± 6.70 years. Mean delivered electrical energy was 25.24 ± 5.33 joules, and mean seizure duration was 39.35 ± 7.52 seconds. All participants had a history of atypical antipsychotic medication use (Table 1).

The total MoCA score increased from 18.00 ± 2.75 before the first ECT session to 21.00 ± 3.13 after six sessions (p=0.001). Visuospatial/executive function, attention, and language improved significantly. Changes in naming, abstraction, delayed recall, and orientation were not statistically significant. The MMSE score increased from 19.88 ± 2.69 to 21.92 ± 2.78 (p=0.001; Table 2).

Comparisons by sex, marital status, education, antipsychotic medication type, clozapine use, and previous ECT history showed no statistically significant differences in MoCA or MMSE scores (p>0.05; Table 3). Pearson correlation analyses found no significant associations between MoCA or MMSE scores and age, illness duration, electrical energy, or seizure duration at either assessment (p>0.05; Table 4).

Table 1. Demographic, clinical, ECT, and medication characteristics

Variable

Category / value

Frequency (%) or mean ± SD

Sex

Male

14 (56%)

Sex

Female

11 (44%)

Age (years)

Mean ± SD

36.72 ± 10.08

Marital status

Single / Married

18 (72%) / 7 (28%)

Education

Below diploma / Diploma / University

13 (52%) / 7 (28%) / 5 (20%)

Illness duration (years)

Mean ± SD

13.56 ± 6.70

ECT electrical energy (joules)

Mean ± SD

25.24 ± 5.33

Seizure duration (seconds)

Mean ± SD

39.35 ± 7.52

Antipsychotic medication

Atypical antipsychotics

25 (100%)

Table 2. MoCA and MMSE scores before and after ECT

Assessment

Domain

Before ECT (mean ± SD)

After ECT (mean ± SD)

p-value

MoCA

Total score

18.00 ± 2.75

21.00 ± 3.13

0.001

MoCA

Visuospatial / executive

2.36 ± 0.56

3.28 ± 0.73

0.001

MoCA

Naming

2.16 ± 0.47

2.40 ± 0.50

0.140

MoCA

Attention

2.04 ± 0.67

2.92 ± 0.70

0.001

MoCA

Language

2.08 ± 0.40

2.48 ± 0.50

0.008

MoCA

Abstraction

1.68 ± 0.47

1.80 ± 0.40

0.083

MoCA

Delayed recall

3.04 ± 0.88

3.32 ± 0.80

0.073

MoCA

Orientation

4.16 ± 0.68

4.36 ± 0.56

0.132

MMSE

Total score

19.88 ± 2.69

21.92 ± 2.78

0.001

Table 3. Comparison of cognitive scores across demographic and clinical groups

The source article reports no statistically significant between-group differences by sex, marital status, education, typical antipsychotic use, clozapine use, or previous ECT history (all p>0.05). The detailed subgroup values are reproduced in the source tables; several numeric cells are affected by right-to-left digit-ordering and extraction inconsistencies, so they have not been silently reconstructed here.

Table 4. Correlations of cognitive scores with clinical variables

Variable

Measure

Assessment

Correlation coefficient

p-value

Illness duration

MoCA

Before

−0.233

0.262

Illness duration

MoCA

After

−0.233

0.262

Illness duration

MMSE

Before

−0.201

0.336

Illness duration

MMSE

After

−0.173

0.409

Age

MoCA

Before

−0.280

0.176

Age

MoCA

After

−0.235

0.258

Age

MMSE

Before

−0.272

0.188

Age

MMSE

After

−0.183

0.381

ECT energy

MoCA

Before

0.659

0.659

ECT energy

MoCA

After

−0.057

0.788

ECT energy

MMSE

Before

−0.070

0.739

ECT energy

MMSE

After

−0.080

0.705

Seizure duration

MoCA

Before

0.041

0.844

Seizure duration

MoCA

After

0.339

0.097

Seizure duration

MMSE

Before

0.135

0.521

Seizure duration

MMSE

After

0.295

0.153

Discussion

In this study, both MoCA and MMSE scores improved significantly after six ECT sessions compared with baseline. This finding is consistent with Tor et al. (2017), who reported significant improvements in MoCA and Brief Psychiatric Rating Scale scores among patients with schizophrenia after ECT. It also agrees with Seow et al. (2019), who observed improvement in total MoCA scores, particularly in executive, visuospatial, and attention domains, after a six-session ECT course. Isserles et al. (2020) and Chan et al. (2019) likewise reported clinical and cognitive improvement following ECT. [29, 23, 32, 9]

Other research has described benefits beyond cognitive scores. Lin et al. (2018) found that ECT was associated with reduced readmissions and emergency visits over one year, although it did not significantly affect length of stay or treatment costs. Kalisova et al. (2018), in a different patient population, also reported improved MoCA performance after six ECT sessions. A systematic review by Ong and Chan (2022) found that cognitive impairment may occur immediately after ECT but generally resolves within the first few weeks. Richard and colleagues’ meta-analysis similarly suggested that new learning may be temporarily impaired, with group mean scores returning to baseline within approximately 14 days, while other cognitive functions are less affected. [15, 34]

Not all studies have found cognitive improvement. Danenberg et al. (2021) reported no significant difference in MoCA scores between ECT-treated patients with longstanding schizophrenia and controls. Petrides et al. (2015) also found no significant between-group change in MMSE scores in patients with clozapine-resistant schizophrenia. Differences in patient selection, ECT technique, treatment parameters, and assessment timing may help explain these inconsistent findings. [33, 35]

In the present study, age, sex, education, marital status, antipsychotic type, and previous ECT history were not significantly associated with cognitive outcomes. These findings are broadly consistent with Seow et al. and other studies cited by the authors, although Patel et al. (2025) reported fewer cognitive difficulties among patients with higher education. The study also found no significant correlations between delivered electrical energy or seizure duration and cognitive scores. The seizure durations observed were within the recommended range, which may partly explain the absence of an adverse cognitive association. [39, 40]

Potential mechanisms for cognitive improvement after ECT include increased release and regulation of neurotransmitters, particularly dopamine, serotonin, and glutamate; changes in neural-network connectivity and cortico-subcortical integration; increased neuroplasticity; modulation of hippocampal activity; and reduction in psychotic symptoms. These mechanisms may indirectly improve attention, memory, and executive functioning.

This study had limitations, including a shortage of hospital beds, which restricted recruitment, and interruptions caused by the COVID-19 pandemic. Larger studies are recommended to investigate how ECT characteristics influence cognitive outcomes and to examine patients with treatment-resistant cognitive symptoms.

Conclusion

A six-session course of ECT was associated with reduced cognitive deficits in patients with schizophrenia. The greatest improvements were observed in the visuospatial/executive, attention, and language domains. The findings suggest that ECT may improve cognitive deficits in schizophrenia rather than necessarily worsening memory function.

Ethical Considerations

This study was derived from a general medical doctoral dissertation at Golestan University of Medical Sciences and was approved under ethics code IR.GOUMS.REC.1399.287. Written informed consent was obtained from participants’ legal guardians.

Data Availability

The data generated in this study are included in the tables.

Funding

This study received no financial support.

Authors’ Contributions

Mohammad Zaman Kamkar and Aghdas Sadat Alavian contributed to conceptualization and study design. Aghdas Sadat Alavian collected the data and prepared the initial draft. Yasmin Ghelichi analyzed and interpreted the data. Mohammad Zaman Kamkar and Yasmin Ghelichi critically reviewed the manuscript.

Conflict of Interest

The authors declared no conflict of interest.

Acknowledgments

The authors thank the Vice-Chancellery for Research and Technology of Golestan University of Medical Sciences, the Psychiatry Research Center, the Clinical Research Development Unit of 5th Azar Hospital in Gorgan, and all study participants.

References

  1. Sadock BJ, Sadock VA, Ruiz P. offset Kaplan & Sadock's comprehensive textbook of psychiatry. 2017. Link
  2. Busner J, Targum SD. The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry (Edgmont). 2007;4(7):28-37. pmid
  3. Orsolini L, Pompili S, Volpe U. Schizophrenia: a narrative review of etiopathogenetic, diagnostic and treatment aspects. J Clin Med. 2022;11(17):5040. doi: 10.3390/jcm11175040 pmid
  4. Aoki N, Tajika A, Suwa T, Kawashima H, Yasuda K, Shimizu T, et al. Relapse following electroconvulsive therapy for schizophrenia: A systematic review and meta-analysis. Schizophr Bull. 2026;52(1):sbae169. doi: 10.1093/schbul/sbae169 pmid
  5. Grover S, Sahoo S, Rabha A, Koirala R. EST in schizophrenia: a review of the evidence. Acta Neuropsychiatr. 2019;31(3):115-27. doi: 10.1017/neu.2018.32 pmid
  6. de Mangoux GC, Amad A, Quilès C, Schürhoff F, Pignon B. History of ECT in schizophrenia: from discovery to current use. Schizophr Bull Open. 2022;3(1):sgac053.  doi: 10.1093/schizbullopen/sgac053 pmid
  7. Leiknes KA, Jarosh-von Schweder L, Høie B. Contemporary use and practice of elestroconvulsive therapy worldwide. Brain Behav. 2012;2(3):283-344. doi: 10.1002/brb3.37 pmid
  8. Weiner R, Lisanby SH, Husain MM, Morales OG, Maixner DF, Hall SE, et al. National network of depression centers. elestroconvulsive therapy device classification: response to fda advisory panel hearing and recommendations. J Clin Psychiatry. 2013;74(1):38-42. doi: 10.4088/JCP.12cs08260 pmid
  9. Chan CYW, Abdin E, Seow E, Subramaniam M, Liu J, Peh CX, et al. Clinical effectiveness and speed of response of electroconvulsive therapy in treatment‐resistant schizophrenia. Psychiatry Clin Neurosci. 2019;73(7):416-22 doi: 10.1111/pcn.12855 pmid
  10. Nygren A, Reutfors J, Brandt L, Bodén R, Nordenskjöld A, Tiger M. Response to electroconvulsive therapy in treatment-resistant depression: nationwide observational follow-up study. BJPsych Open. 2023;9(2):35. doi: 10.1192/bjo.2023.5 pmid
  11. Abrams R. Electroconvulsive therapy. Oxford University Press. 2002. Link
  12. Thornton A, Leathem J, Flett R. Cognitive Assessment during a Course of Elestroconvulsive Therapy-A National Questionnaire Survey of Current Practice in Aotearoa. New Zealand Journal of Psychology.2014; 43(2). Link
  13. Prudic J. Strategies to minimize cognitive side effests with EST: aspests of EST technique. J EST. 2008;24(1):46-51.  doi: 10.1097/YCT.0b013e31815ef238 pmid
  14. Robertson H, Pryor R. Memory and cognitive effests of EST: informing and assessing patients. Advances in Psychiatric Treatment. 2006;12(3):228-37. doi: 10.1192/apt.12.3.228
  15. Ong Y, Chan LG. A systematic review on cognitive effects of electroconvulsive therapy in Asian patients. Clin Psychopharmacol Neurosci. 2022;20(1):1.  doi: 10.9758/cpn.2022.20.1.1 pmid
  16. Bassa A, Sagués T, Porta-Casteràs D, Serra P, Martínez-Amorós E, Palao DJ, et al. The neurobiological basis of cognitive side effects of electroconvulsive therapy: a systematic review. Brain Sci. 2021;11(10):1273. doi: 10.3390/brainsci11101273 pmid
  17. Landry M, Moreno A, Patry S, Potvin S, Lemasson M. Current practices of electroconvulsive therapy in mental disorders: a systematic review and meta-analysis of short and long-term cognitive effects. J ECT. 2021;37(2):119-27. doi: 10.1097/YCT.0000000000000723 pmid
  18. Kritzer MD, Peterchev AV, Camprodon JA. Electroconvulsive therapy: mechanisms of action, clinical considerations, and future directions. Harv Rev psychiatry. 2023;31(3):101-13. doi: 10.1097/HRP.0000000000000365 pmid
  19. Borgers T, Enneking V, Klug M, Garbe J, Meinert H, Wulle M, et al. Long-term effects of electroconvulsive therapy on brain structure in major depression. Psychol Med. 2024;54(5):940-50. doi: 10.1017/S0033291723002647 pmid
  20. Fujita A, Nakaaki S, Segawa K, Azuma H, Sato K, Arahata K, et al. Memory, attention, and executive functions before and after sine and pulse wave elestroconvulsive therapies for treatment-resistant major depression. J EST. 2006;22(2):107-12. doi: 10.1097/00124509-200606000-00006 pmid
  21. Donahue AB. Elestroconvulsive therapy and memory loss. JAMA. 2007;298(16):1862. doi: 10.1001/jama.298.16.1862-a pmid
  22. Shawn M. The effects of electroconvulsive therapy on neurocognitive function in elderly adults. HMP Education. 2011. Link
  23. Seow LSE, Subramaniam M, Chan YWC, Martin DM, Abdin E, Chong SA, et al. A retrospestive study of cognitive improvement following elestroconvulsive therapy in schizophrenia inpatients. J EST. 2019;35(3):170-7. doi: 10.1097/YCT.0000000000000569 pmid
  24. Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, et al. The montreal cognitive assessment, moca: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005 Apr;53(4):695-9. doi: 10.1111/j.1532-5415.2005.53221.x. Erratum in: J Am Geriatr Soc. 2019;67(9):1991. doi: 10.1111/j.1532-5415.2005.53221.x pmid
  25. Badrkhahan SZ, Sikaroodi H, Sharifi F, Kouti L, Noroozian M. Validity and reliability of the Persian version of the Montreal Cognitive Assessment (MoCA-P) scale among subjects with Parkinson's disease. Appl Neuropsychol Adult. 2020;27(5):431-439. doi: 10.1080/23279095.2019.1565762 pmid
  26. Duro D, Simões MR, Ponciano E, Santana I. Validation studies of the portuguese experimental version of the montreal cognitive assessment (moca): confirmatory factor analysis. J Neurol. 2010;257(5):728-34. doi: 10.1007/s00415-009-5399-5 pmid
  27. Foroughan M, Jafari Z, Shirin Bayan P, Ghaem Magham Farahani Z, Rahgozar M. Validation of mini- mental state examination (mmse) in the elderly population of tehran. Adv Cogn Sci. 2008;10(2):29-37. Link
  28. Lopez MN, Charter RA, Mostafavi B, Nibut LP, Smith WE. Psychometric properties of the folstein mini-mental state examination. Assessment. 2005;12(2):137-44. doi: 10.1177/1073191105275412 pmid
  29. Tor PC, Ying J, Ho NF, Wang M, Martin D, Ang CP, et a. Effestiveness of elestroconvulsive therapy and associated cognitive change in schizophrenia: a naturalistic, comparative study of treating schizophrenia with electroconvulsive therapy. J EST. 2017;33(4):272-7. doi: 10.1097/YCT.0000000000000422 pmid
  30. Lin HT, Liu SK, Hsieh MH, Chien YL, Chen IM, Liao SC, et al. Impacts of elestroconvulsive therapy on 1-year outcomes in patients with schizophrenia: a controlled, population-based mirror-image study. Schizophr Bull. 2018;44(4):798-806. doi: 10.1093/schbul/sbx136 pmid
  31. Kalisova L, Kubinova M, Michalec J, Albrecht J, Madlova K, Raboch J. Cognitive functioning in patients treated with elestroconvulsive therapy. Neuropsychiatr Dis Treat. 2018;14:3025-31. doi: 10.2147/NDT.S182423 pmid
  32. Isserles M, Remington J, Kaster TS, Daskalakis ZJ, Blumberger DM. Clinical effestiveness of maintenance elestroconvulsive therapy in patients with schizophrenia: a retrospestive cohort study. J EST. 2020;36(1):42-6. doi: 10.1097/YCT.0000000000000613 pmid
  33. Danenberg R, Ruimi L, Shelef A, Paleacu Kertesz D. A pilot study of cognitive impairment in longstanding elestroconvulsive therapy-treated schizophrenia patients versus controls. J EST. 2021;37(1):24-9. doi: 10.1097/YCT.0000000000000710 pmid
  34. Porter RJ, Baune BT, Morris G, Hamilton A, Bassett D, Boyce P, et al. Cognitive side-effests of elestroconvulsive therapy: what are they, how to monitor them and what to tell patients. BJPsych Open. 2020;6(3):40. doi: 10.1192/bjo.2020.17 pmid
  35. Petrides G, Malur C, Braga RJ, Bailine SH, Schooler NR, Malhotra AK, et al. Elestroconvulsive therapy augmentation in clozapine-resistant schizophrenia: a prospestive, randomized study. Am J Psychiatry. 2015;172(1):52-8. doi: 10.1176/appi.ajp.2014.13060787. 4 pmid
  36. Braga RJ, John M, Schooler NR, Bailine SH, Malur C, Mendelowitz A, et al. Continuation electroconvulsive therapy for patients with clozapine-resistant schizophrenia: a pilot study. J ECT. 2019;35(3):156-60. doi: 10.1097/YCT.0000000000000588 pmid
  37. Tor PC, Bin Abdin E, Hadzi-Pavlovic D, Loo C. Relief of expressed suicidality in schizophrenia after elestroconvulsive therapy: A naturalistic cohort study. Psychiatry Res. 2020;284:112759. doi: 10.1016/j.psychres.2020.112759
  38. Youn T, Jeong SH, Kim YS, Chung IW. Long-term clinical efficacy of maintenance elestroconvulsive therapy in patients with treatment-resistant schizophrenia on clozapine. Psychiatry Res. 2019; 273:759-766. doi: 10.1016/j.psychres.2019. 02. 008 pmid
  39. Patel H, Patel P, Patel R, Kanaujiya N, Chandrani K, Murugan Y. Cognitive function changes during a course of electroconvulsive therapy in patients with various psychiatric illnesses: A prospective observational study. Ind Psychiatry J. 2025;34(2):303-8. doi: 10.4103/ipj.ipj_332_24 pmid
  40. Arunpongpaisal S, Sangsirilak A. Using MoCA-Thai to evaluate cognitive impairment in patients with schizophrenia. J Med Assoc Thai. 2013;96(7):860-5. Link

Copyright © The Author(s). Published under the journal’s stated open-access license.